Schedule Dispatches

Schedule dispatches give a summary of changes coming out in the next month.

On this page

This is an early notification of the changes to be announced in the Update to the Pharmaceutical Schedule.

The full Update is available as a PDF(external link)

The changes will be published in the online Schedule around the 23rd of this month and are effective from next month.

For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz

New Listings

  • Atropine sulphate (Hikma) inj 600 mcg per ml, 1 ml ampoule – up to 5 inj available on a PSO, s29 and wastage claimable (p’code 2693976)
  • Budesonide with glycopyrronium and eformoterol (Breztri Aerosphere) aerosol inhaler budesonide 160 mcg with glycopyrronium 7.2 mcg and formoterol 5 mcg per dose, 120 dose OP – Special Authority – Retail pharmacy (p’code 2656841)
  • Calcitriol (Calcitriol-AFT S29) cap 0.25 mcg – s29 and wastage claimable (p’code 2695154)
  • Covid-19 vaccine (Comirnaty Omicron (JN.1)) inj 10 mcg bretovameran per 0.3 ml, 0.48 ml vial; paediatric vaccine, light blue cap (p’code 2697386); inj 3 mcg bretovameran per 0.3 ml, 0.48 ml vial; infant vaccine, yellow cap (p’code 2697378) and inj 30 mcg bretovameran per 0.3 ml, 0.48 ml vial; adult vaccine, light grey cap (p’code 2697394) – Xpharm, access criteria applies
  • Cytarabine (Pfizer) inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist (p’code 2695758)
  • Eftrenonacog alfa [recombinant factor IX] (Alprolix) inj 250 iu vial (p’code 2696150), inj 500 iu vial (p’code 2696169), inj 1,000 iu vial (p’code 2696177), inj 2,000 iu vial (p’code 2696185), inj 3,000 iu vial (p’code 2696193) and inj 4,000 iu vial (p’code 2696207) – Xpharm
  • Flecainide acetate (Tambocor German) inj 10 mg per ml, 15 ml ampoule – s29 and wastage claimable (p’code 2696967) 
  • Osimertinib (Tagrisso) tab 40 mg (p’code 2536358) and tab 80 mg (p’code 2536331) – Special Authority – Retail pharmacy
  • Palivizumab (Synagis) inj 100 mg per ml, 1 ml vial – PCT only – Special Authority (p’code 2621835)
  • Promethazine hydrochloride (Phenergan Elixir) oral liq 1 mg per ml, 100 ml (p’code 692700)
  • Risperidone (Risperdal) tab 4 mg – Safety medicine (p’code 245402)
  • Sodium fusidate [fusidic acid] (Fucithalmic S29) eye drops 1%, 5 g OP – s29 (p’code 2697572)
  • Solifenacin succinate (Solifenacin succinate Max Health) tab 5 mg (p’code 2690608) and tab 10 mg (p’code 2690616)
  • Trastuzumab deruxtecan inj 100 mg per ml, 1 ml vial (Enhertu) (p’code 2678276) and inj 1 mg for ECP (Baxter) (p’code 2697610) – PCT only – Special Authority

Changes to restrictions, chemical names and presentations

  • Atorvastatin (Lorstat) tab 10 mg, 20 mg, 40 mg and 80 mg – removal of stat dispensing
  • Continuous glucose monitor (interoperable) sensor (9) and transmitter (Dexcom G6), sensor (Dexcom G7) and sensor (Freestyle Libre 3 Plus) – removal of brand switch fee
  • Continuous glucose monitor (standalone) sensor (Dexcom ONE+) and sensor (Freestyle Libre 2) – removal of brand switch fee
  • Durvalumab inj 50 mg per ml, 2.4 ml and 10 ml vial (Imfinzi) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
  • Erlotinib (Alchemy) tab 100 mg and 150 mg – amended Special Authority criteria
  • Ethinyloestradiol with norethisterone (Alyacen) tab 35 mcg with norethisterone 1 mg and 7 inert tab – removal of s29 and wastage claimable
  • Ethinyloestradiol with norethisterone (Alyacen and Brevinor 1/28) tab 35 mcg with norethisterone 1 mg and 7 inert tab – removal of brand switch fee
  • Gefitinib (Iressa) tab 250 mg – amended Special Authority criteria
  • Itraconazole (Itraconazole Kent) oral liq 10 mg per ml, 150 ml OP – amended brand name
  • Methadone hydrochloride tab 5 mg (Methadone BNM), oral liq 2 mg per ml, 200 ml (Biodone), oral liq 5 mg per ml, 200 ml (Biodone Forte), oral liq 10 mg per ml, 200 ml (Biodone Extra Forte) and inj 10 mg per ml, 1 ml (AFT) – removal of note
  • Norethisterone (Norethinderone – CDC, Noriday and Noriday 28) tab 350 mcg – removal of brand switch fee
  • Pegfilgrastim (Ziextenzo AU) inj 6 mg per 0.6 ml syringe – removal of s29 and wastage claimable
  • Trastuzumab emtansine inj 100 mg and 160 mg vial (Kadcyla) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
  • Venlafaxine (Enlafax XR) cap 37.5 mg, 75 mg and 150 mg – removal of stat dispensing

Increased subsidy

Chemical

Presentation

Fully subsidised brands

Amiloride hydrochloride

Oral liq 1 mg per ml, 25 ml OP

Biomed

Caffeine citrate

Oral liq 20 mg per ml (10 mg base per ml), 25 ml OP

Biomed

Cetirizine hydrochloride

Oral liq 1 mg per ml, 200 ml

Histaclear

Clomipramine hydrochloride

Cap 10 mg and 25 mg

Clomipramine Teva

Chlorothiazide

Oral liq 50 mg per ml, 25 ml OP

Biomed

Cyclopentolate hydrochloride

Eye drops 1%, 15 ml OP

Cyclogyl

Dexamethasone

Oral liq 1 mg per ml, 25 ml OP

Biomed

Econazole nitrate

Crm 1%, 20 g OP

Pevaryl

Erythromycin ethyl succinate

Tab 400 mg and

Grans for oral liq 200 mg and 400 mg per 5 ml, 100 ml

E-Mycin

Folic acid

Oral liq 50 mcg per ml, 25 ml OP

Biomed

Hydrocortisone acetate

Rectal foam 10%, CFC-Free (14 applications), 15 g OP

Colifoam

Iron polymaltose

Inj 50 mg per ml, 2 ml ampoule

Ferrosig

Lidocaine [lignocaine] hydrochloride

Inj 1%, 5 ml ampoule and

Inj 2%, 5 ml ampoule

Lidocaine-Baxter

Methylphenidate hydrochloride 

Tab immediate-release 10 mg

Ritalin

Methylphenidate hydrochloride extended-release

Cap modified-release

10 mg, 20 mg, 30 mg and 40 mg

Ritalin LA

Mifepristone

Tab 200 mg

Mifegyne

Potassium citrate

Oral liq 3 mmol per ml, 200 ml OP

Biomed

Spironolactone

Oral liq 5 mg per ml, 25 ml OP

Biomed

Sodium bicarbonate

Inj 8.4%, 50 ml and 100 ml

Biomed

Sodium chloride

Inj 23.4% (4 mmol/ml), 20 ml ampoule

Soln 7%, 90 ml OP

Biomed

Tropicamide

Eye drops 0.5% and 1%, 15 ml OP

Mydriacyl

Decreased subsidy        

Chemical

Presentation

Fully subsidised brands

Mitomycin C

Inj 5 mg vial

Mitomycin (Fresenius Kabi)